Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

Abstract

Negative symptoms of schizophrenia are debilitating and they contribute to poor outcome in schizophrenia. Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest.

Method: A review of the current 'state-of-play' of pharmacological treatments for negative symptoms in schizophrenia.

Results: Treatment results to date have been largely disappointing. The evidence for efficacy of second-generation antipsychotics is reviewed.

Conclusion: The measurement and treatment trials methodology for the evaluation of negative symptoms need additional refinement before therapeutic optimism that better treatments for negative symptoms can be realized.